Shionogi-Backed Apnimed Seeks to Raise $160 Million in US IPO
Apnimed Inc., a late-stage drug developer focused on sleep apnea, is seeking to raise as much as $160 million in a US initial public offering.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.